Search Results for citation:"86 FR 9535"

S&B Pharma, Inc. has applied to the Drug Enforcement Administration (DEA) to be registered as an importer of certain controlled substances. The company intends to import intermediate forms of Tapentadol for manufacturing purposes and ANPP to produce other controlled substances, but they will not import finished products for commercial sale. Interested parties, such as registered manufacturers, can submit comments, objections, or request a hearing regarding this application by March 18, 2021.

The U.S. International Trade Commission has decided not to review a ruling by the administrative law judge allowing changes to a complaint in an investigation concerning artificial eyelash extension systems. The original complaint by Lashify, Inc. claimed that certain products were imported or sold in the U.S., infringing on some of their patents. The investigation originally named CVS Health Corporation and Ulta Beauty, Inc. as respondents, but the ruling allows substituting them with CVS Pharmacy, Inc. and Ulta Salon, Cosmetics & Fragrance, Inc. This decision means the investigation will proceed with these updated parties, and authority for this determination comes from the Tariff Act of 1930.

The United States International Trade Commission (ITC) has determined that removing tariffs on hand trucks and certain parts from China would likely harm U.S. industry. The decision was based on a review process outlined in the Tariff Act of 1930. The review began on July 1, 2020, and finished in February 2021, concluding that keeping the tariffs is necessary to prevent significant damage to the U.S. market.